Bionomics Limited is reporting that their experimental drug BNC210, a novel α7 nicotinic acetylcholine receptor modulator, ...

A groundbreaking antipsychotic, a powerful new antibiotic, and a vaccine-like prophylactic for HIV are some of the most ...

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

When a snake comes across a mongoose, its natural instinct is to attack and kill it or disable it by using its venom or ...

Mongooses and snakes are locked in an evolutionary arms race. Mongooses, with their agility, venom resistance, and protective ...

According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...

Nicotinic receptors are also present on the postsynaptic junctional folds, opposite the sites on the nerve endings from which acetylcholine is released. These nicotinic receptors are composed of ...

An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...

Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics ...

Title: Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune Trial Presenter: Murray ...

Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social ...